Cancer

Nanotechnology helps track down micrometastases missed by MRI

Lack of faith in the healthcare system could be causing non-adherence in cancer patients

Precision medicine often relies on population databases – but are they precise enough?

Mutations in four main genes influence survival rates of pancreatic adenocarcinoma patients

It’s time to accept that ovarian cancer doesn’t exist – and to address the knowledge gap in pelvic cancers

A collaborative challenge aims to address the problem of medication adherence by predicting adverse treatment events.

We talk to Maria Montes-Bayón about mentors and the role of mass spectrometry in the field of human health.

When it comes to identifying cancerous tissue, is the “MasSpec Pen” mightier than the sword?

Improving cancer drugs by “manufacturing” therapeutic compounds using gold nanoparticle catalysts.

Eleftherios P. Diamandis, Hold ’em for Life Chair in Prostate Cancer Biomarkers, University of Toronto.